AbbVie's upadacitinib (RINVOQ(R)) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease

Glyscend Therapeutics Completes Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment

TikoMed AB enters into strategic collaboration with IQVIA

Iveric Bio Presents Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura in Patients with Geographic Atrophy

International Pregistry Study Examines Treatments Used for COVID-19 During Pregnancy

Santen's Verkazia 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States

Horizon Therapeutics Receives European Commission Approval of Uplizna for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder

Gilead, Dragonfly Forge Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation

AbbVie receives FDA for RINVOQ to treat adults with active ankylosing spondylitis

Valbiotis Announces the First Visit of the First Patient in the TOTUM•63 Mode of Action Clinical Study Conducted by the INAF1, in Partnership with Nestlé Health Science

Aruna Bio names new chief executive officer

Quanterix Granted Breakthrough Device Designation from US FDA for NfL Test for Multiple Sclerosis

Samsara Vision to Initiate a US PMA Supplemental Study of the SING IMT, a New-Generation Technology for Age-Related Macular Degeneration

Neuromyelitis Optica Linked to Antibody Exposure During Fetal Development, Feinstein Institutes Study Finds

INRAE and MaaT Pharma Build on Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial